Novo Nordisk A/S (NYSE:NVO) Raised to Buy at Kepler Capital Markets

Novo Nordisk A/S (NYSE:NVO) was upgraded by Kepler Capital Markets from a “hold” rating to a “buy” rating in a report issued on Thursday,Briefing.com Automated Import reports.

A number of other equities research analysts also recently issued reports on NVO. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Stifel Nicolaus downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Finally, StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Stock Down 4.3 %

Novo Nordisk A/S stock opened at $74.75 on Thursday. The company has a market capitalization of $335.42 billion, a PE ratio of 22.72, a PEG ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a 12-month low of $73.80 and a 12-month high of $148.15. The firm’s fifty day moving average is $84.39 and its 200 day moving average is $103.83. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Hedge Funds Weigh In On Novo Nordisk A/S

Large investors have recently modified their holdings of the business. Daiwa Securities Group Inc. bought a new position in Novo Nordisk A/S in the 3rd quarter worth approximately $28,000. Center for Financial Planning Inc. lifted its position in shares of Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after acquiring an additional 123 shares in the last quarter. Strategic Investment Solutions Inc. IL boosted its holdings in shares of Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock worth $27,000 after acquiring an additional 300 shares during the period. Park Square Financial Group LLC purchased a new position in shares of Novo Nordisk A/S in the fourth quarter valued at $29,000. Finally, Transce3nd LLC purchased a new stake in Novo Nordisk A/S during the 4th quarter worth about $33,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.